-
公开(公告)号：EP2858990B1
公开(公告)日：2018-05-16
申请号：EP13731212.0
申请日：2013-06-11
申请人： AbbVie Inc.
发明人： HUBBARD, Robert, D. , WANG, Le , PARK, Chang, H. , SUN, Chaohong , MCDANIEL, Keith, F. , PRATT, John, K. , SOLTWEDEL, Todd, N. , WENDT, Michael, D. , HOLMS, John, H. , LIU, Dachun , SHEPPARD, George, S.
IPC分类号： C07D403/12 , C07D401/14 , C07D213/74 , C07D213/81 , C07D401/02 , C07D401/04 , C07D401/10 , C07D401/12 , C07D403/04 , C07D237/14 , C07D403/10 , C07D407/04 , C07D407/12 , C07D409/04 , C07D413/10
CPC分类号： A61K31/541 , A61K31/4412 , A61K31/50 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D213/30 , C07D213/64 , C07D213/68 , C07D213/74 , C07D213/81 , C07D237/14 , C07D401/02 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D407/04 , C07D407/12 , C07D409/04 , C07D413/10 , C07D417/04 , C07D417/10 , C07D417/12 , C07D498/04
摘要： The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, J, and X3 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula I.
-
2.发明授权SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES 有权磺酰胺ALS BCL-2选择性的细胞凋亡诱导剂治疗癌症和免疫球蛋白和自身免疫疾病
公开(公告)号：EP2507229B1
公开(公告)日：2016-10-05
申请号：EP10727241.1
申请日：2010-06-01
申请人： AbbVie Inc.
发明人： PARK, Chang, H. , BRUNCKO, Milan , DING, Hong , DOHERTY, George A. , ELMORE, Steven, W. , HASVOLD, Lisa , HEXAMER, Laura , KUNZER, Aaron , MANTEI, Robert, A. , McCLELLAN, William, J. , PARK, Cheol-Min , PETROS, Andrew, M. , SONG, Xiaohong , SOUERS, Andrew, J. , SULLIVAN, Gerard, M. , TAO, Zhi-Fu , WANG, Gary, T. , WANG, Le , WANG, Xilu , WENDT, Michael, D. , HANSEN, Todd, M.
IPC分类号： C07D405/12 , A61K31/404 , A61P35/00 , C07D209/32 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D235/26 , C07D249/04 , C07D295/14 , C07D309/14 , C07D401/12 , C07D295/125 , C07D231/56 , C07D405/14
CPC分类号： C07D401/12 , A61K31/407 , A61K31/495 , A61K31/496 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D209/08 , C07D209/32 , C07D211/58 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D231/56 , C07D235/26 , C07D241/04 , C07D249/04 , C07D295/125 , C07D295/14 , C07D295/155 , C07D309/04 , C07D309/14 , C07D401/06 , C07D403/06 , C07D405/06 , C07D405/12 , C07D405/14 , C07D413/06 , C07D417/12 , C07D471/04 , C07D487/04
-
3.发明授权SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES 有权磺胺ALS BCL-2选择性诱导细胞凋亡的手段治疗癌症和免疫系统疾病的
公开(公告)号：EP2376480B1
公开(公告)日：2016-06-01
申请号：EP09795606.4
申请日：2009-12-04
申请人： AbbVie Inc.
发明人： BRUNCKO, Milan , DING, Hong , DOHERTY, George, A. , ELMORE, Steven, W. , HASVOLD, Lisa , HEXAMER, Laura , KUNZER, Aaron, R. , MANTEI, Robert, A. , MCCLELLAN, William, J. , PARK, Chang, H. , PARK, Cheol-min , PETROS, Andrew, M. , SONG, Xiaohong , SOUERS, Andrew, J. , SULLIVAN, Gerard, M. , TAO, Zhi-fu , WANG, Gary, T. , WANG, Le , WANG, Xilu , WENDT, Michael, D.
IPC分类号： C07D405/12 , A61K31/404 , A61P35/00 , C07D309/14 , C07D215/20 , C07D217/16 , C07D231/56 , C07D401/12 , C07D235/26 , C07D417/12 , C07D249/04 , C07D209/32 , C07D295/125 , C07D295/14 , C07D211/96 , C07D213/64
CPC分类号： C07D405/12 , C07D209/32 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D231/56 , C07D235/26 , C07D249/04 , C07D295/125 , C07D295/14 , C07D309/14 , C07D401/12 , C07D417/12
-
4.发明授权APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES 有权凋亡诱导剂治疗癌症和免疫和自身免疫性疾病
公开(公告)号：EP2376197B1
公开(公告)日：2017-02-15
申请号：EP09768289.2
申请日：2009-12-04
发明人： BRUNCKO, Milan , DAI, Yujia , DING, Hong , DOHERTY, George, A. , ELMORE, Steven, W. , HASVOLD, Lisa , HEXAMER, Laura , KUNZER, Aaron, R. , MANTEI, Robert, A. , MCCLELLAN, William, J. , PARK, Chang, H. , PARK, Cheol-Min , PETROS, Andrew, M. , SONG, Xiaohong , SOUERS, Andrew, J. , SULLIVAN, Gerard, M. , TAO, Zhi-Fu , WANG, Gary, T. , WANG, Le , WANG, Xilu , WENDT, Michael, D. , CZABOTAR, Peter Edward , LESSENE, Guillaume Laurent , COLMAN, Peter Malcom
IPC分类号： A61P35/00 , A61K31/496 , C07D403/12
CPC分类号： C07D405/12 , C07D209/08 , C07D211/58 , C07D213/74 , C07D213/84 , C07D231/56 , C07D235/06 , C07D277/24 , C07D295/30 , C07D309/04 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D471/04
-
5.发明公开APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES 审中-公开APOPTOSEINDUKTOREN ZUR BEHANDLUNG冯KREBS SOWIE VON IMMUN- UND AUTOIMMUNERKRANKUNGEN
公开(公告)号：EP3112361A1
公开(公告)日：2017-01-04
申请号：EP16175661.4
申请日：2009-12-04
发明人： BRUNCKO, Milan , DAI, Yujia , DING, Hong , DOHERTY, George, A. , ELMORE, Steven, W. , HASVOLD, Lisa , HEXAMER, Laura , KUNZER, Aaron, R. , MANTEI, Robert, A. , MCCLELLAN, William, J. , PARK, Chang, H. , PARK, Cheol-Min , PETROS, Andrew, M. , SONG, Xiaohong , SOUERS, Andrew, J. , SULLIVAN, Gerard, M. , TAO, Zhi-Fu , WANG, Gary, T. , WANG, Le , WANG, Xilu , WENDT, Michael, D. , CZABOTAR, Peter Edward , LESSENE, Guillaume Laurent , COLMAN, Peter Malcom
IPC分类号： C07D401/14 , C07D405/14 , C07D213/74 , C07D309/04 , C07D213/84 , C07D235/06 , C07D405/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D277/24 , C07D209/08 , C07D211/58 , C07D295/30 , A61P35/00 , A61K31/496 , C07D231/56
CPC分类号： C07D405/12 , C07D209/08 , C07D211/58 , C07D213/74 , C07D213/84 , C07D231/56 , C07D235/06 , C07D277/24 , C07D295/30 , C07D309/04 , C07D401/14 , C07D405/14 , C07D413/12 , C07D417/12 , C07D471/04
摘要： Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
摘要翻译： 公开了抑制抗凋亡Bcl-2蛋白活性的化合物，含有化合物的组合物和治疗其中表达抗凋亡Bcl-2蛋白的疾病的方法。
-
公开(公告)号：EP2858990A1
公开(公告)日：2015-04-15
申请号：EP13731212.0
申请日：2013-06-11
申请人： AbbVie Inc.
发明人： HUBBARD, Robert, D. , WANG, Le , PARK, Chang, H. , SUN, Chaohong , MCDANIEL, Keith, F. , PRATT, John, K. , SOLTWEDEL, Todd, N. , WENDT, Michael, D. , HOLMS, John, H. , LIU, Dachun , SHEPPARD, George, S.
IPC分类号： C07D403/12 , C07D401/14 , C07D213/74 , C07D213/81 , C07D401/02 , C07D401/04 , C07D401/10 , C07D401/12 , C07D403/04 , C07D237/14 , C07D403/10 , C07D407/04 , C07D407/12 , C07D409/04 , C07D413/10
CPC分类号： A61K31/541 , A61K31/4412 , A61K31/50 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D213/30 , C07D213/64 , C07D213/68 , C07D213/74 , C07D213/81 , C07D237/14 , C07D401/02 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D407/04 , C07D407/12 , C07D409/04 , C07D413/10 , C07D417/04 , C07D417/10 , C07D417/12 , C07D498/04
摘要： The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, J, and X3 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula I.
-
公开(公告)号：EP2858990B8
公开(公告)日：2018-07-04
申请号：EP13731212.0
申请日：2013-06-11
申请人： AbbVie Inc.
发明人： HUBBARD, Robert, D. , WANG, Le , PARK, Chang, H. , SUN, Chaohong , MCDANIEL, Keith, F. , PRATT, John, K. , SOLTWEDEL, Todd, N. , WENDT, Michael, D. , HOLMS, James, H. , LIU, Dachun , SHEPPARD, George, S.
IPC分类号： C07D403/12 , C07D401/14 , C07D213/74 , C07D213/81 , C07D401/02 , C07D401/04 , C07D401/10 , C07D401/12 , C07D403/04 , C07D237/14 , C07D403/10 , C07D407/04 , C07D407/12 , C07D409/04 , C07D413/10
CPC分类号： A61K31/541 , A61K31/4412 , A61K31/50 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D213/30 , C07D213/64 , C07D213/68 , C07D213/74 , C07D213/81 , C07D237/14 , C07D401/02 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D407/04 , C07D407/12 , C07D409/04 , C07D413/10 , C07D417/04 , C07D417/10 , C07D417/12 , C07D498/04
摘要： The present invention provides for compounds of formula (I) wherein A1, A2, A3, A4, J, and X3 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, diabetes, obesity, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula I.
-
8.发明公开SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES 审中-公开苏氨酸衍生物ALS BCL-2-SELEKTIVE APOPTOSEINDUKTOREN ZUR BEHANDLUNG VON KREBS SOWIE VON IMMUNERKRANKUNGEN
公开(公告)号：EP3101019A1
公开(公告)日：2016-12-07
申请号：EP16169764.4
申请日：2009-12-04
申请人： AbbVie Inc.
发明人： BRUNCKO, Milan , DING, Hong , DOHERTY, George, A. , ELMORE, Steven, W. , HASVOLD, Lisa , HEXAMER, Laura , KUNZER, Aaron, R. , MANTEI, Robert, A. , MCCLELLAN, William, J. , PARK, Chang, H. , PARK, Cheol-min , PETROS, Andrew, M. , SONG, Xiaohong , SOUERS, Andrew, J. , SULLIVAN, Gerard, M. , TAO, Zhi-fu , WANG, Gary, T. , WANG, Le , WANG, Xilu , WENDT, Michael, D.
IPC分类号： C07D405/12 , A61K31/404 , A61P35/00 , C07D209/32 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D235/26 , C07D249/04 , C07D295/14 , C07D309/14 , C07D401/12 , C07D295/125
CPC分类号： C07D405/12 , C07D209/32 , C07D211/96 , C07D213/64 , C07D215/20 , C07D217/16 , C07D231/56 , C07D235/26 , C07D249/04 , C07D295/125 , C07D295/14 , C07D309/14 , C07D401/12 , C07D417/12
摘要： Disclosed are compounds of formula (I) which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.
摘要翻译： 公开了抑制抗凋亡Bcl-2或Bcl-xL蛋白活性的式（I）化合物，含有该化合物的组合物和治疗其中表达抗凋亡Bcl-2蛋白的疾病的方法。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.045 秒)
